Quantcast

Spit take: Saliva-based glucose monitor Glucose Biosensor Systems re-files for a $23 million US IPO


Shutterstock photo

Glucose Biosensor Systems (Greater China) Holdings, which is developing a saliva-based glucose monitoring system for diabetes in China, filed on Friday with the SEC to raise up to $23 million in an initial public offering.

Glucose Biosensor Systems originally filed to list on the Nasdaq in October 2018 under Regulation A+ in a $9 million to $25 million best-efforts offering with Cuttone & Co serving as placement agent; it withdrew its Reg A+ filing in March 2019.

The New York, NY-based company was founded in 2016 and booked $0.7 million in revenue for the 12 months ended March 31, 2019. It plans to list on the NYSE American under the symbol GBSG. Glucose Biosensor Systems filed confidentially on May 13, 2019. Aegis Capital Corp. is the sole bookrunner on the deal. No pricing terms were disclosed.

The article Spit take: Saliva-based glucose monitor Glucose Biosensor Systems re-files for a $23 million US IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.





This article appears in: News Headlines , IPOs



More from Renaissance Capital

Subscribe







Renaissance Capital
Contributor:

Renaissance Capital

IPOs












Research Brokers before you trade

Want to trade FX?